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Abstract
Background
The impact of nutritional supplements on weight gain in HIV-infected children on antiretrovi-
ral treatment (ART) remains uncertain. Starting supplements depends upon current weight-
for-age or other acute malnutrition indicators, producing time-dependent confounding. How-
ever, weight-for-age at ART initiation may affect subsequent weight gain, independent of
supplement use. Implications for marginal structural models (MSMs) with inverse probability
of treatment weights (IPTW) are unclear.
Methods
In the ARROW trial, non-randomised supplement use and weight-for-age were recorded
monthly from ART initiation. The effect of supplements on weight-for-age over the first year
was estimated using generalised estimating equation MSMs with IPTW, both with and with-
out interaction terms between baseline weight-for-age and time. Separately, data were sim-
ulated assuming no supplement effect, with use depending on current weight-for-age, and
weight-for-age trajectory depending on baseline weight-for-age to investigate potential bias
associated with different MSM specifications.
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Results
In simulations, despite correctly specifying IPTW, omitting an interaction in the MSM
between baseline weight-for-age and time produced increasingly biased estimates as asso-
ciations between baseline weight-for-age and subsequent weight trajectory increased. Esti-
mates were unbiased when the interaction between baseline weight-for-age and time was
included, even if the data were simulated with no such interaction. In ARROW, without an
interaction the estimated effect was +0.09 (95%CI +0.02,+0.16) greater weight-for-age gain
per month’s supplement use; this reduced to +0.03 (-0.04,+0.10) including the interaction.
Discussion
This study highlights a specific situation in which MSM model misspecification can occur
and impact the resulting estimate. Since an interaction in the MSM (outcome) model does
not bias the estimate of effect if the interaction does not exist, it may be advisable to include
such a term when fitting MSMs for repeated measures.
Introduction
Ready-to-use therapeutic food, such as plumpy’nut (Nutriset, Rouen, France), is an energy-
dense, peanut-based paste containing sugar, vegetable fat and skimmed milk powder, fortified
with vitamins and minerals. It was designed, and is widely used, for nutritional rehabilitation
of children with severe acute malnutrition. It is also widely used in stunted/wasted HIV-
infected children entering antiretroviral therapy (ART) programmes [1], under the reasonable
assumption that it will improve growth in children without severe acute malnutrition. Chil-
dren rapidly gain weight after starting ART [2–5], but the causal role of nutritional supple-
ments in this catch-up growth remains unclear.
ARROW was a randomised controlled trial investigating the impact of different manage-
ment strategies in HIV-infected children starting ART in Uganda and Zimbabwe (ISCRTN
24791884) [1]. Within the protocol, plumpy’nut could be provided if considered clinically nec-
essary based on the child’s weight-for-age and other measures of acute malnutrition; it was
available through routine sources. As plumpy’nut was non-randomised and provided at vary-
ing times after ART initiation, evaluating the causal effect of supplementation on weight gain
is complex. Weight-for-age is both the outcome of interest and a key time-dependent con-
founder (amongst others) of the association between cumulative supplement use and weight-
for-age (Fig 1); that is, it is a risk factor for both the exposure and outcome of interest that
changes through time. For example, CD4 count predicts both ART initiation and mortality,
but also increases subsequent CD4 counts. In this situation, standard adjustments for time-
varying CD4 will not correctly estimate the causal effect of ART on mortality, as part of the
treatment effect mediated by CD4 will be removed. If there are further unmeasured common
causes of CD4 and mortality, conditioning on CD4 will induce an association between expo-
sure and these unmeasured common causes, introducing further bias [6–8]. In this applica-
tion, weight-for-age is both the time-varying confounder and the outcome of interest.
Marginal structural models (MSMs) with inverse probability of treatment weighting
(IPTW) are an established causal inference method to address time-dependent confounding
[9], specifically IPTW of generalised estimating equations (GEEs) for repeated measures out-
comes [10].
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However, with repeated measures data, the underlying outcome trajectory (i.e. the trajec-
tory in the absence of intervention) may depend on its starting value; that is, the intercept and
slope may be correlated. For example, independent of supplement use, weight gain after ART
initiation is likely accelerated in children who are initially very underweight due to their HIV
infection, enabling them to “catch-up” at a faster rate than children only slightly underweight
when they start ART.
Both the treatment model and the MSM must be correctly specified for unbiased causal
inference from IPTW MSMs. Under randomisation, omitting a true correlation between inter-
cept and slope from the MSM would not affect the treatment effect estimate. From the existing
literature [10–12], the implications of such dependence between intercept and slope on correct
estimation of the causal effect using IPTW MSM in observational repeated measures data are
unclear, particularly since it is common to stabilise the IPTW with baseline covariates (which
may include the baseline value of the outcome) to reduce the impact of extreme weights. This
results in MSMs that in fact estimate a conditional treatment effect estimate. Although previ-
ous literature [10] highlights the importance of correct MSM specification, inclusion of inter-
actions and baseline covariates in the MSM is discussed in relation to effect modification of
the causal effect of interest only.
Here, we estimate the causal effect of nutritional supplementation on weight gain in HIV-
infected children in their first year on ART, and investigate, using empirical observational data
and simulation, the impact of incorrectly specifying correlated slope and intercept on esti-
mated treatment effects from IPTW GEEs.
Methods
ARROW methods and results have been reported previously [1]. In brief, children aged 3
months to 17 years, who met World Health Organization (WHO) 2006 criteria for initiating
ART [13], were recruited following caregiver consent. Children were randomised to receive
one of three combination ART regimens, and to routine laboratory versus clinically driven
monitoring (factorial randomisation). During the first year on ART, no differences in any trial
outcomes, including weight gain, were observed between randomised groups.
At enrolment (ART initiation) and at 4-weekly follow-up visits, data were collected on clini-
cal and laboratory measures, including weight (from which a standardised score for weight-
for-age is calculated), height and middle-upper-arm-circumference (MUAC). MUAC and cal-
culated weight-for-height are both used to identify malnutrition. HIV-infected children are
often both stunted and wasted so have more normal weight-for-height and therefore weight-
for-age is also used when assessing malnutrition. Children considered to have malnutrition at
any visit could be supplied with the protein-based supplement “plumpy’nut” at standard doses
at the clinician’s discretion, provided this was available through routine sources (not provided
by the trial). In Zimbabwe, children were referred to national malnutrition programmes for
Fig 1. Graphical representation of assumed association between weight-for-age and use of nutritional
supplementation following ART initiation in HIV-infected children.
https://doi.org/10.1371/journal.pone.0233877.g001
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plumpy’nut. This analysis was therefore restricted to the three Ugandan study sites (Entebbe,
Joint Clinical Research Centre (JCRC), Paediatric Infectious Diseases Clinic (PIDC)) that pro-
vided the supplement through the ARROW clinic and therefore recorded all use consistently.
Analysis included only children enrolled after December 2007, when supplement use was
added to case record forms. Finally, only children under 6 years at enrolment were included,
as only 1/98 Ugandan children over 6 years were ever given plumpy’nut. Including older chil-
dren would lead to large IPTW due to positivity assumption violation (essentially perfect pre-
diction of treatment initiation) which may bias the causal estimate [9]. Follow-up was to the
minimum of 12 months, death or withdrawal/lost to follow-up.
Data were organised into 4-weekly intervals, corresponding to scheduled visits. Few sched-
uled visits were missed (6%) and therefore missing values for covariates and plumpy’nut use
were imputed by carrying the most recent observation forward when fitting the weighting
models and calculating cumulative plumpy’nut use.
Due to positivity violations, it was not possible to model binary on/off treatment in each 4
weekly period. As such, weight estimation required the exposure process to be coarsened. The
IPTW were calculated by first estimating the probability of initiating plumpy’nut in each
monthly interval in those who had not yet initiated (“initiation model”), estimated using logis-
tic regression. Baseline predictors of weight-for-age trajectory included in the initiation model
were age, gender, CD4%, WHO stage, primary carer, weight-for-age (z-score), and a combined
MUAC/weight-for-height indicator for malnutrition (< 0.8 times expected weight-for-height,
or low MUAC (<12.5cm if <5 years, <14.5cm if 5–6 years); used when children were enrolled
during 2007–2008). Time-dependent predictors were CD4%, previous weight-for-age, hospita-
lisation since last visit and MUAC/weight-for-height malnutrition indicator. Weight-for-age
and weight-for-height z scores were calculated using WHO references [14]. CD4% and
weight-for-age were included as linear continuous covariates. Time (weeks since ART initia-
tion) was included as a linear spline with a knot at 16 weeks based on the trajectory of overall
increases in weight-for-age [1, 5]. Age was included as a natural cubic spline with knots at the
25th, 50th and 75th percentiles. All baseline covariates and time were used to calculate numera-
tors for the stabilised weights [10]. These weights were estimated separately by study site, to
allow for potential differences in prescribing indications.
These initiation weights effectively assume a treatment probability of one for all visits after
plumpy’nut is first started (i.e., that children remained on plumpy’nut continually post-initia-
tion). As durations of plumpy’nut use varied (see S1 Table in S2 Appendix), we then estimated
additional weights to account for stopping plumpy’nut (“stopping model”). Subsequent re-
starting after stopping was only observed in 4 children and therefore was not considered fur-
ther. Due to data sparsity, we could not model stopping at every visit after initiation or sepa-
rately by site. 31% of children stopped plumpy’nut after just one month; therefore we
calculated stopping weights based on the probability of continuing after 1 month’s use vs stop-
ping after 1 month only. These probabilities were estimated from a logistic regression fitted for
the month following plumpy’nut initiation only. Since this model was not compatible with
modelling each child’s observed treatment duration, we assumed that children continuing had
6 months of plumpy’nut use in total, which was the median duration in those that did not stop
after 1 month. To test the model’s sensitivity to this assumption, we also considered 3 and 9
months’ use in sensitivity analyses. Baseline predictors in the stopping model were: weight-
for-age (continuous linear), centre, CD4% (<16%, 16–23%, >23%), primary carer, age (natu-
ral cubic spline), sex, WHO stage (4 vs lower), and MUAC/weight-for-height malnutrition
indicator. Time-varying covariates included previous weight-for-age (continuous linear),
change in CD4% from baseline (<0%, 0–15%,>15%), hospitalisation since last visit, and
MUAC/weight-for-height malnutrition indicator. As for initiation weights, time was included
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as a linear spline with a knot at 16 weeks, and all baseline risk factors and time were used to cal-
culate numerators for the stabilised weights [10]. Initiation and stopping weights were multi-
plied together to give the final IPTW. In those that never initiated plumpy’nut, their time-
varying weight was determined by the initiation weight only. Loss-to-follow up/death was
minimal (5% by one year), and therefore additional weighting to adjust for censoring was not
included.
The effect of cumulative plumpy’nut use on change in weight-for-age (i.e. additional gain in
weight-for-age per months’ extra plumpy’nut) was estimated using an IPTW GEE [10] with an
independent working correlation matrix. We used an independent working correlation matrix
in our analyses because exchangeable correlation structures in GEEs may give biased estimates
when past outcome affects future exposure as is the case here [15, 16]. Other parametric associ-
ations with cumulative use (e.g. non-linear) were considered but there was no evidence that
more complex relationships improved model fit (assessed via a wald test of all additional non-
linear terms and examination of the magnitude of the estimates). All baseline covariates used
for weight stabilisation were included in the GEE [17] and, as such, the estimand of interest
was the average causal effect of 1 months plumpy’nut on weight-for-age conditional on all
included baseline covariates listed above and time [11]. Weighted GEEs were compared to
unweighted GEEs to assess the potential impact of time-dependent confounding on the esti-
mated effect of supplement use on weight gain. Both weighted and unweighted GEEs were fit-
ted with and without an interaction between time and baseline weight-for-age to allow for
dependence between underlying weight gain (in the absence of supplementation) and baseline
weight-for-age. Other interactions between baseline covariates and time or cumulative plum-
py’nut use were included where heterogeneity p<0.05. Missed visits where weight-for-age had
been carried forward (6% of observations) were not included in the GEEs.
The algebraic specification of all weights and the MSM are provided in S1 Appendix.
Simulation study
Our focus was on estimating the treatment effect and, in particular, the bias associated with
different analysis methods, rather than variance, which is important for ultimate inference but
less so the greater the bias. We therefore simulated a single sample of 200,000 children, with
normally distributed baseline weight-for-age z-scores (mean -2, variance 2.25). Simulation
parameters for weight-for-age were chosen so that simulated data approximated ARROW
data. Weight-for-age at monthly follow-up visits through 1 year was simulated to depend only
on the previous weight-for-age and time, with no effect of supplement use, based on the
observed mean change per month (0.1 z score increase per month). Supplement initiation was
simulated to depend upon current weight-for-age and baseline weight-for-age. Stopping sup-
plement was simulated to depend on current weight-for-age only (Eqs 1 & 2, Box 1). Simula-
tion parameters for treatment initiation and subsequent stopping were not based on ARROW
data, but chosen to produce time-dependent confounding without strong positivity violations.
As a control simulation, supplement initiation was simulated to follow a sequential randomisa-
tion process with a fixed probability of initiation of 0.2 at each time-point for all who had not
yet initiated (Eqs 3 & 4, Box 1) and all subjects remained on plumpy’nut for a minimum of 4
months or until 1 year from ART initiation.
The dependence between baseline weight-for-age and underlying weight gain (here equal
to overall weight gain as data were simulated with no supplement effect) was then varied to
assess its impact on the bias of the estimator of the causal effect of supplement use. This
included a scenario where there was no dependence. This was done firstly by adding an inter-
action term into the underlying model, and secondly by drawing random intercepts (baseline)
PLOS ONE MSMs with IPTW for repeated measures with correlated intercept and slope
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Box 1. Formal notation for simulated data.
Main simulation: (1) Treatment allocation and (2) stopping dependent upon baseline
and/or current weight-for-age. Control simulation: (3) Treatment allocated under
sequential randomisation and stopping (4) dependent upon duration of use only.
Define Wij to be the random variable for weight-for age for subject i at time j
(j = 0,1,2,. . .,12), with W0 therefore defined as the baseline weight-for age, and define wij
to be the observed weight-for age for subject i at time j. Let Aij be random variable repre-
senting treatment for subject i at time j, where A takes the value 0 or 1 to represent the
presence of absence of nutritional supplements respectively. Then the data were simu-
lated using parameters which reflected the data observed in the ARROW trial as follows,
assuming an underlying weight-for-age increase of 0.1 units per month:
a Fixed effect model with interaction:
W0 � Nð  2; s
2 ¼ 2:25Þ
Wij ¼ wij  1 þ 0:1þ xwi0 þ gAij  1 þ εij
εij � Nð0; 0:09Þ8i; j
x = 0, -0.05, -0.1, or -0.2 is the magnitude of the interaction between baseline weight and
time, and γ = 0, 0.1, 0.2 or 0.3 is the treatment effect per month extra of supplement use.
1. Random slope simulation model
Wi0
Si
�
  2
0
;
2:25 0:06r
0:06r 0:0016
0
B
@
0
B
@
1
C
A
1
C
A
r ¼ 0;   0:1;   0:3;   0:5;   0:8 or   1; and g ¼ 0; 0:1; 0:2 or 0:3
Wij ¼ wij  1 þ ð0:1þ SiÞþgAij  1 þ εij
εij � Nð0; 0:09Þ8i; j
For both a) and b):
logitðPðAijjAij  1 ¼ 0ÞÞ ¼   1:5   1wij   0:1wi0 ð1Þ
logitðPðAij ¼ 0jAij  1 ¼ 1ÞÞ ¼   1:38þ 0:5wij ð2Þ
Or
PðAijjAij  1 ¼ 0Þ ¼ 0:2 ð3Þ
PðAij ¼ 0jAij  1 ¼ 1Þ ¼ 0 if
Xj
t¼0
aij  1 < 4; and 1 otherwise ð4Þ
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and slopes from a bivariate normal distribution (random slope distribution mean 0, and stan-
dard deviation (SD) based on the estimated SD of the slope in ARROW data). In sensitivity
analyses, we repeated the simulations with varying effects of supplementation on weight gain.
Box 1 shows formal notation for the simulated data. Current weight-for-age was simulated
as a function of previous and baseline weight-for-age, time, plus a random error. This ensured
that current weight-for-age was associated with previous weight-for-age even after time and
baseline weight-for-age were accounted for, as would occur in reality due to unmeasured fac-
tors (e.g. economic status, food security, family structures) that may also affect weight gain. All
simulation code is provided in S4 Appendix.
Once the simulated data were obtained, we fitted the weighting models using the correct
model specification, and then applied the estimated weights to the repeated measures MSM
using generalised estimating equations as in the application. Two models were fitted to all sim-
ulation scenarios. In both, weight for age was the outcome, and plumpy’nut use, baseline
weight for age, and time were fitted as main effects. An interaction between baseline weight for
age and time was only included in the second model. As such, the estimator of interest in all
simulation scenarios, including true randomisation of treatment, was the average treatment
effect of plumpy’nut conditional on baseline weight-for-age and time.
Four GEEs (with independent working correlation matrix) were then fitted to investigate
biases in estimating the effect of plumpy’nut on weight gain.
Model-1: Unweighted GEE adjusting for visit and baseline weight-for-age
Model-2: Unweighted GEE adjusting for visit, baseline weight-for-age and their interaction
Model-3 IPTW (MSM) estimated via GEE, excluding an interaction term between baseline
weight-for-age and visit in the MSM.
Model-4: IPTW (MSM) estimated via GEE including an interaction term between baseline
weight-for-age and visit in the MSM.
All analyses were conducted using Stata version 14 [18].
The ARROW trial data used for this analysis are provided in S5 Appendix. Code to generate
the simulated data are provided in S4 Appendix. This study is a re-analysis of data collected in
a trial and so there is no specific ethical approval for the analysis. Caregivers provided written
informed consent to enter the original trial. The original trial was approved by ethics commit-
tees in Uganda (Joint Clinical Research Centre Institutional Review Board), Zimbabwe (Medi-
cal Research Council of Zimbabwe), the UK (University College London Research Ethics
Committee) and the US (Baylor College of Medicine Institutional Review Board).
Results
Cohort characteristics
385 Ugandan children were enrolled in ARROW during the study period. 98 were excluded as
they were�6 years at enrolment, and 4 because they did not have baseline MUAC recorded.
Of the 283 children included in the analysis, 63 (22%) initiated plumpy’nut before 12 months
on ART, although one initiated it at the 12-month visit. As anticipated, children receiving
plumpy’nut were younger, more malnourished and had more advanced HIV disease (Table 1).
Fig 2 provides example trajectories of weight-for-age. Those ever prescribed plumpy’nut
started and ended their first year on ART at lower weight-for-age, but also tended to have
greater increases in weight-for-age. Excepting weeks 20 and 28, those initiating plumpy’nut at
each monthly visit had a lower mean current and previous weight-for-age compared to non-
initiators (Table 2). Although the single initiator at weeks 20 and 28 had a higher weight-for-
age than the mean in non-initiators, their weight-for-age was reduced versus the previous
month.
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Application
Distributions of the stabilised initiation, stopping, and combined weights are shown in
Table 3, with full weighting models in S2–S5 Tables in S2 Appendix. For the initiation weights
for JCRC, baseline MUAC/weight-for-height indicator was a perfect predictor of receiving
plumpy’nut and was therefore omitted from this weighting model. For each site, the mean ini-
tiation weight was close to 1, with none over 5 (Table 3). Similarly, the mean stopping and
overall combined weight was approximately one. Since there were no extreme weights, they
were not truncated.
Table 4 presents the estimated conditional average treatment effect of one month’s addi-
tional plumpy’nut use on a child’s expected change in weight-for-age per month for the four
GEEs (full model outputs in S6 Table in S2 Appendix). Models 1 and 2 are estimated from an
unweighted GEE, with independent working correlation matrix. Model 1 includes main effect
Table 1. Baseline (at ART initiation) characteristics of included children in the ARROW trial (enrolled after December 2007 aged<6 years at enrolment, from
three study sites in Uganda (Entebbe, JCRC and PIDC)) (N = 284).
Mean (SD) [range] at ART initiation Ever used plumpy’nut in first 48 weeks on ART
No (N = 221) Yes (N = 63) Total (N = 284)
Age (years) 2.89 (1.56) 1.86 (1.24) 2.66 (1.55)
[0.4,5.92] [0.49, 5.54] [0.4, 5.92]
Weight-for-age -1.58 (1.27) -3.85 (1.38) -2.08 (1.6)
[-5.28, +2.29] [-9.12, -1.03] [-9.12, +2.29]
Height-for-age -2.38 (1.45) -3.62 (1.3) -2.66 (1.51)
[-7.39, +2.04] [-7.07, -0.77] [-7.39, +2.04]
Weight-for-height -0.43 (1.29) -2.59 (1.31) -0.91 (1.57)
[-5.36, +2.63] [-4.75, +0.29] [-5.36, +2.63]
Middle upper arm circumference (MUAC) (cm) 14.5 (2.3) 11.8 (1.7) 13.9 (2.4)
[9.6, 36] [8.2, 16] [8.2, 36]
CD4%a 15.5 (8.2) 14.1 (8.0) 15.2 (8.1)
[1, 42] [1, 33] [1, 42]
N (%)
Gender
Male 101 (46) 30 (48) 131 (46)
Female 120 (54) 33 (52) 153 (54)
Primary Carer
Mother 158 (71) 48 (76) 206 (73)
Other 63 (29) 15 (24) 78 (27)
WHO stage at ART initiation
1 7 (3) 2 (3) 9 (3)
2 98 (44) 4 (6) 102 (36)
3 87 (39) 31 (49) 118 (42)
4 29 (13) 26 (41) 55 (19)
Low MUAC/weight-for-height compositeb
No 181 (82) 14 (22) 195 (69)
Yes 40 (18) 48 (77) 88 (31)
a truncated at 1st and 99th percentile.
b composite score indicating presence of either low weight for height (< 0.8 x expected weight-for-height) or low MUAC for age (<12.5cm if <5 and <14.5cm if 5–6
years).
https://doi.org/10.1371/journal.pone.0233877.t001
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adjustments for time since ART initiation, age, gender, baseline weight-for-age, baseline
CD4%, baseline malnutrition indicator, baseline WHO stage, centre, and primary carer.
Model 2 is as model 1 but also including an interaction between baseline weight-for-age and
time in weeks since ART initiation. Models 3 and 4 are the IPTW equivalents of models 1 and
2 respectively. No other interaction terms tested had a heterogeneity of p<0.05 so were not
included. In the weighted GEE without interactions between baseline weight-for-age and time
(model 3), the estimates increase slightly compared to the unweighted model (model 1)
although confidence intervals overlap, with an expected additional 0.09 (95% CI 0.02, 0.16)
weight-for-age gain per month’s extra use of plumpy’nut. However, when baseline weight-for-
age is allowed to independently affect weight-for-age trajectory through an interaction
Fig 2. Random sample of trajectories of weight-for-age (Z-score) from children enrolled in ARROW trial after
December 2007 from Ugandan sites (Entebbe, JCRC, PIDC) aged<6 years at enrolment, who never initiated
plumpy’nut (A) and who initiated plumpy’nut at some point during the first year on ART (B).
https://doi.org/10.1371/journal.pone.0233877.g002
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Table 2. Mean (SD) weight-for-age in initiators and non-initiators of plumpy’nut at each monthly visit in the ARROW trial (in those not yet initiated and not lost
to follow up by this time).
Current weight-for-age Previous month’s weight-for-age
Week since ART initiation Non-initiator this month Initiator this month Non-initiator this month Initiator this month
0 (Baseline) n = 283 n = 0
-2.05 (1.52)
4 n = 251 n = 32 n = 251 n = 32
-1.69 (1.36) -3.69 (1.12) -1.82 (1.42) -3.92 (0.98)
8 n = 236 n = 14 n = 236 n = 14
-1.39 (1.22) -3.36 (1.31) -1.56 (1.27) -3.68 (1.30)
12 n = 230 n = 4 n = 230 n = 4
-1.24 (1.16) -3.05 (0.69) -1.35 (1.20) -3.41 (1.20)
16 n = 227 n = 2 n = 227 n = 2
-1.14 (1.11) -2.45 (2.37) -1.22 (1.14) -3.22 (3.07)
20 n = 226 n = 1 n = 226 n = 1
-1.09 (1.09) -0.76 -1.14 (1.11) -0.5
24 n = 225 n = 1 n = 225 n = 1
-0.97 (1.07) -2.78 -1.08 (1.09) -1.89
28 n = 224 n = 1 n = 224 n = 1
-0.95 (1.06) -0.15 -0.98 (1.07) 0.17
32 n = 221 n = 3 n = 221 n = 3
-0.88 (1.03) -2.65 (1.70) -0.92 (1.02) -2.89 (2.20)
36 n = 221 n = 0 n = 221 n = 0
-0.84 (0.98) -0.88 (1.03)
40 n = 218 n = 2 n = 218 n = 2
-0.81 (0.95) -1.99 (1.79) -0.83 (0.98) -1.99 (2.01)
44 n = 216 n = 2 n = 216 n = 2
-0.77 (0.94) -1.22 (0.37) -0.81 (0.95) -1.26 (0.29)
48 n = 209 n = 1 n = 209 n = 1
-0.73 (0.88) -2.74 -0.77 (0.91) -4.14
https://doi.org/10.1371/journal.pone.0233877.t002
Table 3. Distribution of stabilised IPTW estimated separately by study site in the ARROW trial.
Mean SD Percentiles Min Max
Weights for treatment initiation 1st 10th 50th 90th 99th
Entebbe 0.98 0.62 0.19 0.99 1.44 2.3 4.29 0.19 4.29
JCRC 0.99 0.33 0.26 1.00 1.04 1.24 2.19 0.26 3.83
PIDC 1.03 0.51 0.26 1.00 1.11 1.25 3.63 0.18 4.71
Weight for stopping after 1 month vs continue�
All centres combined 1.02 0.43 0.34 0.78 0.92 1.00 1.01 0.34 3.67
Combined start/stop weight
All centres combined 1.00 0.44 0.23 0.50 1.00 1.12 3.14 0.16 4.71
Factors included in each model are as follows: Denominator: baseline age, gender, baseline CD4%, baseline WHO stage, primary carer, baseline weight-for-age, and
baseline MUAC/weight-for-height indicator for malnutrition (< 0.8 x expected weight-for-height or low MUAC (<12.5cm if <5 years or <14.5cm if 5–6 years)), CD4%
at last visit, weight-for-age at last visit, hospitalisation since last visit and low MUAC/weight-for-height indicator at last visit. Numerator: baseline age, gender, baseline
CD4%, baseline WHO stage, primary carer, baseline weight-for-age, and baseline MUAC/weight-for-height indicator for malnutrition (< 0.8 x expected weight-for-
height or low MUAC (<12.5cm if <5 years or <14.5cm if 5–6 years)).
�(based on 62 data points of those who took plumpy’nut for 1 month or more before 12 months from starting ART.
https://doi.org/10.1371/journal.pone.0233877.t003
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(model-4), the estimate of plumpy’nut effectiveness reduces to 0.03 (-0.04, +0.10), in fact very
similar to the equivalent unweighted estimates (model 2). Without the interaction (model 3),
the result of the IPTW GEE is borderline statistically significant; whilst no firm conclusions on
a positive effect of plumpy’nut could be drawn, this is consistent with a previous study that
found a positive effect of plumpy’nut using a different statistical approach [19]. However, in
relative terms, as well as being far from statistically significant, the estimate of effect is reduced
by around 67% when the interaction was included (model 4), leading to a qualitatively differ-
ent interpretation. Sensitivity analyses assuming 3 or 9 rather than 6 months’ use in those not
stopping after a one month gave similar results (S7 and S8 Tables in S2 Appendix)
Simulation study
Simulation results were similar under both fixed and random effect simulation scenarios (Fig
3). Simulated weight-for-age trajectories were smoother than in ARROW as expected; and
more simulated children ever received supplementation. For example in the random effect
simulation, 60% and 95% of children received supplements in the first month or by one year
respectively. These differences are likely because of the lack of other factors influencing treat-
ment and weight gain in the relatively simple simulation, in contrast to the observed data.
Unweighted GEEs all showed very large negative bias, demonstrating the key impact of not
adjusting for time-dependent confounding (Fig 3, S9 and S10 Tables in S3 Appendix). How-
ever, weighted MSM GEEs not including the interaction between baseline weight-for-age and
time were positively biased, with bias increasing as the correlation between baseline weight-
for-age and trajectory increased. In comparison, the weighted MSM GEEs including the
Table 4. Estimates of effect of supplement use, time and baseline weight-for-age on growth per month from unweighted GEE (1,2) and IPTW weighted GEE (3,4)
in the ARROW trial.
Unweighted full
baseline adjustment (1)
Unweighted full baseline
adjustment with interaction
(2)
IPTW weighted full
baseline adjustment (3)
IPTW weighted full baseline
adjustment with interaction (4)
Estimate (95%
Confidence Interval)
Estimate (95% Confidence
Interval)
Estimate (95%
Confidence Interval)
Estimate (95% Confidence
Interval)
Cumulative supplement use (per
additional month of plumpy’nut)
0.065 (-0.002, 0.132) 0.022 (-0.047, 0.091) 0.086 (0.017, 0.155) 0.028 (-0.042, 0.098)
Time (per month up to 16 weeks,
regardless of supplement use)
0.041 (0.033, 0.048) 0.012 (0.002, 0.022) 0.040 (0.032, 0.048) 0.013 (0.003, 0.023)
Time (per month post 16 weeks,
regardless of supplement use)
0.013 (0.010, 0.016) -0.0004 (-0.004, 0.003) 0.014 (0.011, 0.017) -0.001 (-0.005, 0.002)
Baseline weight-for-age 0.715 (0.644, 0.787) 0.990 (0.905, 1.075) 0.710 (0.636, 0.784) 0.984 (0.893, 1.074)
Baseline weight-for-age time interaction
(up to 16 weeks, regardless of supplement
use)
-0.015 (-0.020, -0.010) -0.014 (-0.019, -0.009)
Baseline weight-for-age time interaction
(post 16 weeks, regardless of supplement
use)
-0.007 (-0.009, -0.005) -0.008 (-0.010, -0.006)
(1) Adjusted for time, age at ART initiation, gender, baseline CD4%, baseline MUAC/weight-for-height indicator, baseline weight-for-age, primary carer and baseline
WHO stage.
(2) (1) + interaction terms between baseline weight-for-age and both time terms.
(3) (1) including stabilised inverse probability of treatment weights.
(4) (2) including stabilised inverse probability of treatment weights.
All models assume that if plumpy’nut was not stopped after 1 month, it was continued for 6 months. For example, estimates from model (4) indicate that the impact of
1, 2, 3, 4, 5, 6 month’s plumpy’nut use is an additional +0.028, +0.056, +0.084, +0.112, +0.140, +0.168 unit’s weight-for-age Z-score respectively.
https://doi.org/10.1371/journal.pone.0233877.t004
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interaction remained approximately unbiased (Fig 3, S9 and S10 Tables in S3 Appendix). The
bias was greater in the simulation scenarios where the data were generated using an interaction
term rather than a correlated random slope and intercept.
Association between baseline weight-for-age and slope simulated by a bivariate normal dis-
tribution (top) and a fixed effect interaction (bottom). Unweighted no interaction: GEE adjust-
ing for time and baseline weight-for-age (analogous to Model 1 in Table 4). Unweighted with
Fig 3. Effect (95% confidence intervals) of 1 month’s extra plumpy’nut on change in weight-for-age, where the
true effect is zero, under different assumptions concerning the association between baseline weight-for-age and
underlying weight-for-age trajectory (simulated data).
https://doi.org/10.1371/journal.pone.0233877.g003
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interaction: GEE adjusting for time, baseline weight-for-age and their interaction (Model 2 in
Table 4). Weighted no interaction: MSM with IPTW excluding an interaction term between
baseline weight-for-age and time in the MSM (Model 3 in Table 4). Weighted with interaction:
MSM with IPTW including an interaction term between baseline weight weight-for-age and
time in the MSM (Model 4 in Table 4). Red line indicates true simulated effect.]
The same pattern of results was observed when simulating a non-null treatment effect (S9
and S10 Tables in S3 Appendix). Simulating allocation of plumpy’nut randomly at each time
point gave approximately unbiased estimates for all models, even those not including interac-
tion terms (S1 Fig in S2 Appendix, S11 and S12 Tables in S3 Appendix).
Discussion
This study aimed to estimate the causal effect of plumpy’nut on weight-for-age in HIV-
infected children, because it remains uncertain whether nutritional supplements have any
additional impact on weight gain in children starting ART. Lack of consistency of results from
applying MSMs for repeated measures to this real-world example motivated an investigation
of the potential impact of model misspecification due to correlated slope and intercept on bias
in estimates from MSM with IPTW for repeated measures. Via a simple simulation, we showed
that not incorporating correlation between slope and intercept via an interaction term in the
MSM can result in biased causal effect estimates, and bias increases in magnitude with increas-
ing strength of correlation. Further, under simulated randomisation, the same conditional
average treatment effect estimate did not show bias even when the interaction was present in
the data but omitted from the model. In ARROW, adding an interaction term to allow chil-
dren with lower baseline weight-for-age to gain weight faster independently from supplement
use, changed the conditional causal estimate from suggesting a small beneficial effect of sup-
plement use, to no evidence of an effect of supplement use (actual estimate change from +0.09
to +0.03 per months’ extra use).
To our knowledge, this is the first study to specifically address the implications of depen-
dence between intercept and slope in repeated measures data for correctly estimating causal
effects in IPTW MSMs, and the first to estimate the effect of nutritional supplementation on
weight gain in HIV-infected children using these causal methods. A previous study used a ran-
dom effects model with random slope and intercept in a different dataset [19]. The authors did
not specify whether they allowed for correlation between their random slope and intercept;
however they estimated weight-for-age increased by 0.06 per additional months’ supplement
use (95% CI 0.03,0.10). This is consistent with all estimates from the present study, but closest
to the analyses that did not account for the correlation. However, this study included some
older children aged 6–10 years at ART initiation, who were excluded from our analyses due to
positivity violations. These estimates are therefore not directly comparable, although younger
children would be expected to have received supplementation most commonly and therefore
to drive any effects.
To further assess consistency with this previous study, we also fitted an unweighted mixed
effects model, allowing random slopes and random intercepts. This suggested much larger
beneficial effects of plumpy’nut on weight gain, with a 0.13 (95% CI 0.11,0.15) increase in
weight-for-age per months’ additional plumpy’nut assuming independent intercept and slope,
and 0.12 (0.10,0.14) allowing correlation between them. Although in the opposite direction of
the expected time-dependent confounding in this context, these results are similar to those
obtained from an unweighted GEE using an exchangeable working correlation matrix with no
interaction in our study (0.14 (0.08,0.20)); which reduced to 0.06 (-0.01,+0.12) with interac-
tion. We used an independent working correlation matrix in our analyses because
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exchangeable correlation structures in GEEs may give biased estimates when past outcome
affects future exposure as here [15, 16]. It is possible that similar issues arise in the unweighted
mixed effects model.
Both our simulation study and data analysis have limitations. Using a single large sample
for the simulation study avoids small sample bias, but means we did not investigate precision
or variance estimation/coverage. However, our main interest was investigating bias (since the
main goal of IPTW is to reduce this), and the trends in the magnitude of the bias observed
with increasing association between baseline and trajectory are still of interest even in the
absence of information on precision. The simulation could have included other time-varying
confounders (e.g. CD4%, hospitalisation) or baseline confounders (e.g. age, gender) of the
association between plumpy’nut use and weight-for-age. This may have produced differences
between models of more similar magnitude to those in our real-world application, though the
bias in the simpler simulation is still demonstrated.
Strengths include high quality trial data with little missingness. Therefore, important poten-
tial confounders (both baseline and time-varying) were available to fit well-specified models
for treatment initiation and outcome. However, data were insufficient to model treatment
stopping flexibly, and we could only model continuing vs stopping after 1 month, and assume
a fixed average duration of use in everyone that continued. Actual duration is likely informa-
tive in terms of weight-for-age gain, meaning some residual time-dependent confounding may
remain. However sensitivity analyses assuming different durations of use gave similar conclu-
sions clinically and statistically. The choice to impute missing visits in the weighting models
using last observation carried forward was a pragmatic decision based on low numbers of
missing visits and the already complex treatment process requiring the combination of two
weighting models. Given that only 6% of visits were missed, it is unlikely that a substantial bias
was introduced into the weights by using this approach. Use of additional weights for censor-
ing or missingness may be useful to explore in further research as an alternative approach.
Other factors may also have been useful to further control for confounding in both initia-
tion and stopping models, such as food insecurity, overall calorie intake or types of food avail-
able. Additionally, in one site, the baseline indicator for having low MUAC or height-for-age
perfectly predicted treatment initiation, leading to a strict violation of the positivity assump-
tion, and meaning this predictor could not be included in this initiation weighting model.
However, it is unlikely that any serious residual time-dependent confounding remains due to
its omission since, as a baseline variable, it was still included in the MSM. Lastly, also to avoid
strict positivity violations, children aged 6 year or older at ART initiation were excluded from
the analysis; our results are therefore generalizable only to children under 6 years.
The final MSM was considered to be the best possible parsimonious model, but it should be
acknowledged that there may have been some remaining mis-specification, since tests for
other interaction were based on Wald tests that may have been underpowered. Additionally,
the difference between the standard and IPTW analyses in the empirical example were rela-
tively small in magnitude. This could be because most children receiving the supplement initi-
ated it in the first 3 months, and so the effect of post-baseline confounding was not as strong as
initially hypothesised. The models with and without interactions between baseline weight-for-
age and time produced what could be clinically relevant differences in the point estimates of
the benefits of plumpy’nut, which are not explained by any of the limitations above. Due to
some overlap in confidence intervals, random variation cannot be ruled out. However, the
supporting simulation study identifies a clear problem from model misspecification when
baseline and trajectories are associated and interactions are not included in the MSM.
For true causal interpretation, the underlying assumptions of conditional exchangeability,
consistency, no interference and positivity are required to hold [20].Additionally, the correct
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model specification of both weighting and outcome models not only requires the correct
terms in the model, but also that the terms are in the correct parametric form (e.g. linear vs
quadratic). The limitations discussed above suggest that we cannot be confident of satisfying
all of these assumptions, and so caution is needed in interpreting the estimate of the effect of
plumpy’nut on weight gain as entirely causal. However, many of these limitations also apply to
all other studies estimating effects from multivariable models. Notwithstanding, this applica-
tion is still a useful example of how results may change if the MSM is incorrectly specified in
this way. Here, the overall conclusion is only slightly altered (borderline to no evidence of a
beneficial effect), and the bias was quite small in magnitude. However, in other situations the
bias could substantially alter conclusions, and there are many other contexts where our meth-
odological findings may have implications. For example, in untreated asthma, forced expira-
tory volume (FEV) is much lower in severe asthma than mild asthma. The impact of standard
asthma medication (analogous to ART) may have a greater impact on improving severe
asthma than mild asthma, and therefore the slope of change in FEV will be steeper for those
starting at a lower value. Any study using MSMs to investigate the impact of concomitant
medications on FEV change, in addition to standard therapy, would therefore need to consider
this.
Our findings suggest that HIV-infected children initiating ART with low weight-for-age
have no additional weight gain due to nutritional supplementation. This contrasts prior studies
suggesting benefits of nutritional supplementation but without adjusting for time-varying con-
founders [19]. Our data suggest that growth reconstitution in HIV-infected children is medi-
ated primarily by ART. Weight loss in untreated, HIV-infected children is driven by several
factors, including anorexia, reduced intake due to oral pathology, malabsorption, cytokine-
mediated muscle loss, increased metabolic demands and opportunistic infections [21]. ART
initiation leads to reduced immune activation, improved appetite, intestinal repair, and resolu-
tion of opportunistic infections. It appears that the additional nutrition provided by supple-
mentary food does not significantly improve weight gain at a time when ART is fundamentally
altering the physiological milieu, enabling growth reconstitution.
In summary, correct specification of both the IPTW and MSM models is a necessary
assumption for causal interpretation of the resulting estimate. This study highlights a specific
situation in which MSM model misspecification may occur and have an impact on the result-
ing estimate. Due to such misspecification being irrelevant under true randomisation, the
importance of accounting for correlated slope and intercept may not be immediately obvious
to those using MSMs for repeated measures. Additional simulation studies that assess more
complex model specifications, variance, mean square error and coverage are required to pro-
vide concrete recommendations, but our initial findings suggest that since an interaction in
the MSM (outcome) model does not appear to bias the estimate of effect if the interaction does
not exist, it may be advisable to include such a term when fitting MSMs for repeated measures.
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